BRPI0920246A2 - método de preparação de alfa-beta peptídios biologicamente ativos. - Google Patents
método de preparação de alfa-beta peptídios biologicamente ativos.Info
- Publication number
- BRPI0920246A2 BRPI0920246A2 BRPI0920246A BRPI0920246A BRPI0920246A2 BR PI0920246 A2 BRPI0920246 A2 BR PI0920246A2 BR PI0920246 A BRPI0920246 A BR PI0920246A BR PI0920246 A BRPI0920246 A BR PI0920246A BR PI0920246 A2 BRPI0920246 A2 BR PI0920246A2
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- biologically active
- active alpha
- beta peptides
- peptides
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/006—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10620508P | 2008-10-17 | 2008-10-17 | |
| US22932509P | 2009-07-29 | 2009-07-29 | |
| US12/578,993 US8642536B2 (en) | 2008-10-17 | 2009-10-14 | Method of making biologically active alpha-beta peptides |
| PCT/US2009/060659 WO2010045342A1 (en) | 2008-10-17 | 2009-10-14 | Method of making biologically active alpha-beta peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0920246A2 true BRPI0920246A2 (pt) | 2017-06-27 |
Family
ID=41572553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0920246A BRPI0920246A2 (pt) | 2008-10-17 | 2009-10-14 | método de preparação de alfa-beta peptídios biologicamente ativos. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US8642536B2 (pt) |
| EP (1) | EP2337788B1 (pt) |
| JP (2) | JP6265583B2 (pt) |
| KR (1) | KR20110071014A (pt) |
| CN (1) | CN102245625A (pt) |
| AU (1) | AU2009303389B2 (pt) |
| BR (1) | BRPI0920246A2 (pt) |
| CA (1) | CA2740873C (pt) |
| IL (1) | IL212123A (pt) |
| WO (1) | WO2010045342A1 (pt) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012035504A1 (en) * | 2010-09-14 | 2012-03-22 | Ramot At Tel-Aviv University Ltd. | Cell occupancy measurement |
| DK2694095T3 (en) * | 2011-04-05 | 2018-05-28 | Longevity Biotech Inc | COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME |
| US10501518B2 (en) * | 2013-06-23 | 2019-12-10 | Wisconsin Alumni Research Foundation | Alpha-/beta-polypeptide analogs of parathyroid hormone (PTH) and method of using same |
| US20200354428A9 (en) | 2013-06-23 | 2020-11-12 | Wisconsin Alumni Research Foundation | Analogues of parathyroid hormone (1-34) that function as agonists of the parathyroid hormone receptor-1 and display modified activity profiles |
| EP3036261B1 (en) * | 2013-08-21 | 2018-11-14 | UREKA Sarl | Peptide-oligourea chimeric compounds and methods of their use |
| WO2015042272A1 (en) * | 2013-09-18 | 2015-03-26 | Ndsu Research Foundation | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH γ-HERPESVIRUSES |
| WO2015112700A1 (en) * | 2014-01-22 | 2015-07-30 | Wisconsin Alumni Research Foundation | Alpha/beta-peptide mimics of z-domain peptides |
| KR101551143B1 (ko) | 2014-07-28 | 2015-09-08 | 성균관대학교산학협력단 | 생체적합성 단백질, 이를 포함하는 생체적합성 단백질 젤과 전도성 단백질 젤 및 그의 제조방법 |
| WO2016194825A1 (ja) | 2015-05-29 | 2016-12-08 | シスメックス株式会社 | リポタンパク質のコレステロール取り込み能を測定する方法及び試薬キット |
| WO2016207726A1 (en) | 2015-06-22 | 2016-12-29 | Ureka Sarl | Bioinspired catalysis using oligourea helical foldamers |
| WO2017037142A1 (en) | 2015-08-31 | 2017-03-09 | Centre National De La Recherche Scientifique (Cnrs) | Foldamer helix bundle-based molecular encapsulation |
| JP2019519478A (ja) | 2016-04-19 | 2019-07-11 | ユレカ・ソシエテ・ア・レスポンサビリテ・リミテＵｒｅｋａ Ｓａｒｌ | ペプチド−オリゴ尿素フォルダマー化合物及びそれらの使用方法 |
| US10993459B2 (en) | 2019-09-23 | 2021-05-04 | Ralph Yoder | Method for unlocking bioactive proteins |
| EP4419140A1 (en) | 2021-10-22 | 2024-08-28 | Wisconsin Alumni Research Foundation | Peptides that inhibit infection by sars-cov-2, the virus that causes covid-19 disease |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3587151T2 (de) | 1984-12-20 | 1993-07-15 | Sandoz Ag | Behandlung von gastrointestinalkrankheiten durch anwendung von 5-ht3-antagonisten. |
| US4810777A (en) * | 1987-03-04 | 1989-03-07 | The United States Of America As Represented By The Department Of Health And Human Services | Antimicrobial compounds |
| EP0296122B1 (en) | 1987-06-17 | 1993-09-29 | Sandoz Ag | Cyclosporins and their use as pharmaceuticals |
| DE3851268T2 (de) | 1987-06-19 | 1995-01-26 | Sandoz Ag | Zyklische Peptolide. |
| IT1219652B (it) | 1987-06-23 | 1990-05-24 | Sandoz Ag | 8-acilamminoergolina,la sua preparazione e il suo impiego come medicamneto |
| GB2239178B (en) | 1987-07-10 | 1991-11-27 | Sandoz Ltd | Somatostatin analogues for the treatment of breast cancer |
| GB2240476B (en) | 1987-07-11 | 1992-03-18 | Sandoz Ltd | 5 ht-3 antagonists for the prevention or reduction of dependence |
| GB8800397D0 (en) | 1988-01-08 | 1988-02-10 | Sandoz Ltd | Improvements in/relating to organic compounds |
| GB2218102B (en) | 1988-04-08 | 1992-09-16 | Sandoz Ltd | Calcitonin peptide derivatives |
| HU214591B (hu) | 1989-12-14 | 1998-04-28 | Novartis Ag. | Eljárás egy naftoxazinszármazék malonátsójának és az ilyen hatóanyagot tartalmazó gyógyszerkészítmények előállítására |
| DE4033496A1 (de) | 1990-10-20 | 1992-04-23 | Sandoz Ag | Neue ergolinderivate, ihre herstellung und verwendung |
| HUT64023A (en) | 1991-03-22 | 1993-11-29 | Sandoz Ag | Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds |
| DE4131584A1 (de) | 1991-09-23 | 1993-03-25 | Sandoz Ag | Imidazolylmethyl-pyridine, ihre herstellung und anwendung als pharmazeutika |
| DE4139143A1 (de) | 1991-11-28 | 1993-06-03 | Sandoz Ag | Neue benzochinoxaline, ihre herstellung und verwendung |
| AU672790B2 (en) | 1992-07-15 | 1996-10-17 | Novartis Ag | Variants of parathyroid hormone and its fragments |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| WO1994012493A1 (en) | 1992-11-25 | 1994-06-09 | Sandoz, Ltd. | 2,2-dialkyl- and 2,2-dialkyl-3,4-dihydro-3-hydroxy-2h-1-benzopyr ans, their use as pharmaceuticals |
| GB9225396D0 (en) | 1992-12-04 | 1993-01-27 | Sandoz Ltd | Improvements in or relating to organic compounds |
| AU677297B2 (en) | 1993-03-03 | 1997-04-17 | Novartis Ag | Peptide boronic acid derivatives having protease inhibiting activity |
| EP0618223A3 (en) | 1993-03-08 | 1996-06-12 | Sandoz Ltd | Peptides, the release of Interleukin 1-Bêta, useful as anti-inflammatory agents. |
| DE4329776A1 (de) | 1993-09-03 | 1995-03-09 | Sandoz Ag | Naphthoxazine, ihre Herstellung und Verwendung |
| GB9322828D0 (en) | 1993-11-05 | 1993-12-22 | Sandoz Ltd | Organic compounds |
| US7118859B2 (en) * | 1996-01-17 | 2006-10-10 | Progenics Pharmaceuticals, Inc. | Methods for inhibiting HIV-1 infection |
| DE19612805A1 (de) * | 1996-04-01 | 1997-10-02 | Hoechst Ag | Antifungische Peptide aus Scleroderma texense |
| CA2256516C (en) | 1996-06-13 | 2007-09-25 | Novartis Ag | Peptides |
| US20020037997A1 (en) | 1997-03-04 | 2002-03-28 | Gellman Samuel H. | Beta-amino acids |
| US6060585A (en) | 1997-03-04 | 2000-05-09 | Wisconsin Alumni Research Foundation | β-polypeptide foldamers of well-defined secondary structure |
| ES2232196T3 (es) | 1998-12-23 | 2005-05-16 | The Horticulture And Food Research Institute Of New Zealand Limited | Inhibidor de la serin proteasa. |
| US20070154882A1 (en) | 2005-03-10 | 2007-07-05 | Teresa Compton | Beta-polypeptides that inhibit cytomegalovirus infection |
| JP5261178B2 (ja) | 2005-08-26 | 2013-08-14 | ウィスコンシン アルムニ リサーチ ファンデイション | 官能化されたベータラクタムモノマーからのポリ−ベータ−ペプチド及びポリ−ベータ−ペプチドを含有する抗菌組成物 |
| US7820858B2 (en) | 2006-03-25 | 2010-10-26 | Wisconsin Alumni Research Foundation | Concise β2-amino acid synthesis via organocatalytic aminomethylation |
| US9168329B2 (en) | 2006-09-01 | 2015-10-27 | Wisconsin Alumni Research Foundation | Beta-peptides with antifungal activity |
| US9738697B2 (en) * | 2013-06-23 | 2017-08-22 | Wisconsin Alumni Research Foundation | Alpha/beta-polypeptide analogs of glucagon-like peptide-1 |
-
2009
- 2009-10-14 CA CA2740873A patent/CA2740873C/en active Active
- 2009-10-14 EP EP09740804.1A patent/EP2337788B1/en active Active
- 2009-10-14 BR BRPI0920246A patent/BRPI0920246A2/pt not_active Application Discontinuation
- 2009-10-14 CN CN2009801515981A patent/CN102245625A/zh active Pending
- 2009-10-14 JP JP2011532211A patent/JP6265583B2/ja active Active
- 2009-10-14 AU AU2009303389A patent/AU2009303389B2/en active Active
- 2009-10-14 WO PCT/US2009/060659 patent/WO2010045342A1/en not_active Ceased
- 2009-10-14 KR KR1020117011077A patent/KR20110071014A/ko not_active Abandoned
- 2009-10-14 US US12/578,993 patent/US8642536B2/en active Active
-
2011
- 2011-04-04 IL IL212123A patent/IL212123A/en active IP Right Grant
-
2013
- 2013-03-06 US US13/786,673 patent/US10647743B2/en active Active
-
2014
- 2014-01-08 US US14/150,125 patent/US9416156B2/en active Active
-
2015
- 2015-07-17 JP JP2015143213A patent/JP2015193648A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009303389A1 (en) | 2010-04-22 |
| US8642536B2 (en) | 2014-02-04 |
| EP2337788A1 (en) | 2011-06-29 |
| CA2740873C (en) | 2019-09-10 |
| US20140315791A1 (en) | 2014-10-23 |
| JP6265583B2 (ja) | 2018-01-24 |
| US10647743B2 (en) | 2020-05-12 |
| KR20110071014A (ko) | 2011-06-27 |
| CA2740873A1 (en) | 2010-04-22 |
| IL212123A0 (en) | 2011-06-30 |
| AU2009303389B2 (en) | 2014-10-16 |
| JP2012505903A (ja) | 2012-03-08 |
| CN102245625A (zh) | 2011-11-16 |
| US20100099185A1 (en) | 2010-04-22 |
| EP2337788B1 (en) | 2016-03-23 |
| US20130177981A1 (en) | 2013-07-11 |
| US9416156B2 (en) | 2016-08-16 |
| WO2010045342A1 (en) | 2010-04-22 |
| JP2015193648A (ja) | 2015-11-05 |
| IL212123A (en) | 2017-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0920246A2 (pt) | método de preparação de alfa-beta peptídios biologicamente ativos. | |
| BRPI0822775A2 (pt) | Método de obtenção de uma proteína heteróloga, purificada, biologicamente ativa. | |
| DK3115370T3 (da) | Biologisk aktive peptider | |
| DK2307543T3 (da) | Forbedret proteinekspressionssystem | |
| BRPI1014975A2 (pt) | sistema de entrega de implante | |
| PL3050571T3 (pl) | Preparat enzymu trawiennego do leczenia rzucawki | |
| BRPI1014885A2 (pt) | "azetidinil diamidas como inibidores de monoacilglicerol lipase." | |
| BRPI0919090A2 (pt) | prepraração de ácido acético. | |
| SG10201401995UA (en) | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies | |
| HUE062860T2 (hu) | Magas koncentrációjú gyógyszerészeti készítmények | |
| BR112012003716A2 (pt) | estruturas de implante porosas | |
| BR112012006414A2 (pt) | método de preparação de proteína derivados de plantas | |
| BRPI0908439A2 (pt) | sistema de implante mamário | |
| IT1391555B1 (it) | Apparato trattamento extracorporeo sangue | |
| IT1400544B1 (it) | Procedimento di detossificazione di tessuto biologico. | |
| BRPI1009447A2 (pt) | métodos de purificação de proteínas imunofarmacêuticas modulares pequenas | |
| SMT201500142B (it) | Procedimento per la purificazione di proteine | |
| BR112012022879A2 (pt) | composto, composição farmacêutica, uso do composto e método de tratamento | |
| BRPI0921947A2 (pt) | formulações de proteína terapêutica | |
| BRPI1013975A2 (pt) | método e sistema de implante endoscópico. | |
| DK2207790T3 (da) | Biologisk aktive C-terminalt argininholdige peptider | |
| EP2557088A4 (en) | PHYSIOLOGICALLY ACTIVE PEPTIDES | |
| BRPI1010121A2 (pt) | método de tratamento biológico | |
| EP2270141A4 (en) | Lacritin PART PEPTIDE | |
| GB0817507D0 (en) | Protein cages |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |